Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) traded down 1.4% during trading on Wednesday . The stock traded as low as $0.85 and last traded at $0.8960. 12,932 shares were traded during mid-day trading, a decline of 52% from the average session volume of 26,783 shares. The stock had previously closed at $0.9087.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Read Our Latest Research Report on GDTC
CytoMed Therapeutics Price Performance
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
See Also
- Five stocks we like better than CytoMed Therapeutics
- Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
- Survey Reveals: America’s Top Autumn Activities that are Free [2026]
- Defying Gravity: Space Stocks Reach Escape Velocity
- Credo Technology Just Plunged 20%—Did the Market Overreact?
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
